Want to see DTIL full AI Analyst Report?
Top Page
Precision BioSciences
(NASDAQ:DTIL)
Select Model
Select Model
Rating:54Neutral
Price Target:
$8.00
▲(1.52% Upside)
Action:Reiterated
Date:07/01/26
The score is held down primarily by weak financial performance (continued losses and negative free cash flow). Offsetting this, the stock shows a strong upward technical trend (price above all key moving averages with bullish MA stacking) and corporate updates are positive (promising HBV data and extended debt maturity). Valuation remains a secondary drag because losses make the negative P/E hard to interpret and there is no dividend support.
Positive Factors
Proprietary ARCUS platform and focused pipeline
A proprietary, platform-based genome editing technology provides durable competitive advantage: it supports multiple internal programs and collaboration revenue streams, enables repeatable R&D efficiencies, and increases optionality from licensing and partner-funded development across high-unmet-need indications.
Negative Factors
Persistent negative operating and free cash flow
Ongoing cash burn creates durable funding dependency: the company must repeatedly access capital or partner funding to advance trials. This raises dilution and refinancing risk, constrains discretionary investment, and limits ability to self-fund late-stage development absent material revenue or milestone inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ARCUS platform and focused pipeline
A proprietary, platform-based genome editing technology provides durable competitive advantage: it supports multiple internal programs and collaboration revenue streams, enables repeatable R&D efficiencies, and increases optionality from licensing and partner-funded development across high-unmet-need indications.
Read all positive factors
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$211.06M
Dividend YieldN/A
Average Volume (3M)328.46K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth-11.87%
EPS Growth-86.91%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.35
Shares Outstanding25,802,246
10 Day Avg. Volume363,888
30 Day Avg. Volume328,457
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$32.25Price Target Upside309.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.81
Revenue Forecast (FY)$20.48M
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary gen...
How the Company Makes Money
Precision BioSciences generates revenue primarily through collaboration and licensing arrangements tied to its ARCUS genome editing platform rather than from product sales (as it has been a clinical-stage company). These arrangements typically inc...
Precision BioSciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.07M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 43.70M | 31.51M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -40.42M | -42.43M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -44.48M | -46.61M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | ||||||
| Total Assets | 143.89M | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 101.18M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 28.47M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 67.79M | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 76.10M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | ||||||
| Free Cash Flow | -58.78M | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -58.73M | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -434.00K | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 85.22M | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Technical Analysis
Positive
7.88
Price Trends
7.14
Positive
6.33
Positive
5.76
Positive
Market Momentum
0.25
Negative
67.61
Neutral
80.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 7.88 is above the 20-day moving average (MA) of 6.89, above the 50-day MA of 7.14, and above the 200-day MA of 5.76, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 67.61 is Neutral, neither overbought nor oversold. The STOCH value of 80.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precision BioSciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $211.06M | -1.88 | -81.24% | ― | -11.87% | -86.91% | |
52 Neutral | $68.85M | -1.26 | -35.20% | ― | ― | 49.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $831.63M | -10.58 | -36.61% | ― | -75.91% | -173.33% | |
47 Neutral | $84.13M | -0.60 | -80.35% | ― | ― | 27.27% | |
44 Neutral | $73.62M | -0.86 | -64.43% | ― | ― | 9.80% |
* Healthcare Sector Average
DTIL
Precision BioSciences
8.18
3.87
89.79%
CTMX
CytomX Therapeutics
3.82
1.45
61.18%
ACET
Adicet Bio
9.00
-1.38
-13.34%
IMA
ImageneBio
5.83
-10.37
-64.01%
ACRV
Acrivon Therapeutics, Inc.
1.72
0.47
37.60%
Precision BioSciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B
Positive
Jul 1, 2026
Precision BioSciences, Inc. is a biotechnology company focused on developing gene-editing therapies targeting serious chronic and genetic diseases. Its pipeline includes programs for chronic hepatitis B and Duchenne muscular dystrophy, positioning...
Business Operations and StrategyPrivate Placements and Financing
Precision BioSciences Extends Term Loan Maturity to 2029
Positive
Jun 16, 2026
On June 10, 2026, Precision BioSciences, Inc. amended its existing loan and security agreement with Banc of California, entering into a first amendment that modifies the terms of its term loan facility. Under the revised agreement, the maturity da...
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Reports Promising New Hepatitis B Trial Data
Positive
May 27, 2026
On May 27, 2026, Precision BioSciences reported new and late-breaking clinical and biopsy data from its ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B, presented at the European Association for the Study of the Liver Congre...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Precision BioSciences Shareholders Approve Incentive Plan and Directors
Positive
May 26, 2026
On May 21, 2026, Precision BioSciences held its annual meeting of stockholders, where shareholders approved an amended and restated 2019 Incentive Award Plan that increases the pool of shares available for equity-based compensation by 3,800,000 sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.